Loading clinical trials...

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory | Clinical Trials | Clareo Health

TERMINATEDNA

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

NCT04294888•Massachusetts General Hospital

Summary

The purpose of this study is to assess the effects of non-invasive brain stimulation on memory in cognitively unimpaired older adults and in patients amnestic mild cognitive impairment (aMCI) due to Alzheimer's disease (AD). This study will use repetitive Transcranial Magnetic Stimulation (rTMS) to stimulate nodes of the Default Mode Network (DMN)- which is thought to support episodic memory and to be affected by Alzheimer's pathology. We will use functional connectivity MRI (fcMRI) to assess changes in functional network architecture following the stimulation. We will also assess putative cognitive improvements resulting from the stimulation by in-depth memory testing.

Eligibility

Age

60 - 85 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Between the ages of 60-85
•2. All participants will be native English speakers
•3. Willing and able to consent to the protocol and undergo imaging and neuropsychological testing at the specified time points
•4. Participants with aMCI will be asked to bring a study partner to all visits
•5. Only patients with very mild or mild cognitive impairment (CDR 0.5 or CDR 1) will be included in the prodromal AD cohort

Exclusion Criteria

•1. History of head trauma involving loss of consciousness or alteration in consciousness
•2. Another major neurologic or psychiatric condition
•3. Known presence of a structural brain lesion (e.g. tumor, cortical infarct)
•4. Any contraindication to MRI, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body
•5. Longstanding premorbid history (i.e. longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
•6. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the study protocol.
•7. Unwilling to return for follow-up, undergo neuropsychological testing, TMS, and MR imaging

Locations (1)

Massachuetts General Hospital

Charlestown, Massachusetts, United States

Key Dates

Start Date

March 2, 2020

Primary Completion Date

June 23, 2021

Completion Date

June 23, 2021

Last Updated

March 20, 2026

Enrollment

ACTUAL participants

Conditions

Alzheimer DiseaseMild Cognitive ImpairmentAging

Interventions

repetitive transcranial magnetic stimulation (rTMS)

DEVICE

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 20, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

TMS in Preclinical and Prodromal AD: Modulation of Brain Networks and Memory

Inclusion Criteria

Exclusion Criteria

Sense4Safety Intervention

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Targeting Aging With a Ketone Ester for Function in Frailty

Ultrasound Image Bank: Advancing Medical Research and Diagnostics

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment